Le Lézard
Classified in: Health, Covid-19 virus
Subject: AVO

Front Line COVID-19 Critical Care Alliance Statement on Misleading FDA Guidance on Ivermectin


WASHINGTON, March 7, 2021 /PRNewswire-PRWeb/ -- The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, is troubled by the recently updated consumer guidance on Ivermectin from the FDA. The guidance from the FDA is misleading and has the potential to raise unwarranted concern over an important drug in the prevention and treatment of COVID-19.

We support the FDA's direction that humans should never take medication formulations meant for animals. We also agree that self-dosing of medications without the guidance of a physician is potentially dangerous and could cause serious harm.

However, the FLCCC feels that other statements recently made by the FDA are misleading and serve to alarm the public about using Ivermectin as a treatment prescribed by a physician.

The FDA consumer guidance statement admits that they have not reviewed data on the use of Ivermectin to treat or to prevent COVID-19. However, the agency felt compelled to use language to discourage any discourse and interest in using Ivermectin as a front-line treatment of COVID-19. To do this is to ignore the growing body of scientific evidence from peer-reviewed research, over 40 medical trials, and results from Ivermectin's use in medical settings worldwide, showing the safe and effective use of the drug in fighting COVID-19. [Source available here]

According to the American Medical Association Journal of Ethics, 10-20% of all prescriptions in the U.S. are prescribed 'off-label." [Source available here] Ivermectin is often one of many drugs prescribed by a physician for a number of conditions it is known to be effective for, but might not have gone through FDA approval. It is therefore misleading to suggest that because a drug has not received FDA approval for COVID it should not be used. FDA approval would only come many months to years from now after a very large Phase III trial is done and our patients cannot wait for that.

"Due to its extensive record of safe use, medical professionals can feel confident about prescribing Ivermectin," said Dr. Pierre Kory, president and chief medical officer of the FLCCC. "In the 40 years since it was first approved for use, more than 3.8 billion people have been treated with an average of only 160 adverse events reported per year. [Source available here] This is a better safety record than several vitamins."    

During this time of a pandemic, the FDA should be working as fast as it can to approve the use of Ivermectin in the prevention and treatment of COVID-19 instead of issuing misleading guidance that could prevent people from taking a life-saving drug. In the meantime, the public deserves to have clear and science-based information on safe and effective treatments for COVID-19.

About the Front Line COVID-19 Critical Care Alliance
The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned Critical Care physician/scholars ? with the academic support of allied physicians from around the world ? to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. Their MATH+ Hospital Treatment Protocol, introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19. Now, the FLCCC's new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with Ivermectin has been released ? and is a potential solution to the global pandemic.
For more information: http://www.FLCCC.net

Media Contact

Joyce Kamen, [email protected], +1 513-486-4696, [email protected]

 

SOURCE [email protected]


These press releases may also interest you

at 05:35
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical...

at 05:30
Blockbuster growth in weight-loss drugs was the main driver of a 13.5% increase in spending on prescription medications in the U.S. in 2023, according to ASHP's (American Society of Health-System Pharmacists) report, National Trends in Prescription...

at 05:26
Renowned orthopedic surgeon Dr. Dror Paley, in partnership with Dr. León Mora and the Cora Group Excellence Center for Orthopedic Reconstructive and Limb Lengthening Surgery, is...

at 05:15
The Industrial Technology Research Institute (ITRI) triumphed at the recent Edison Awardstm in Fort Myers, Florida, securing recognition for four exceptional technological breakthroughs: the Novel Dual-Targeted Therapy for Glaucoma, Key Functional...

at 05:00
The Beta-Glucan Market is estimated at USD 542 million in 2024 and is projected to reach USD 800 million by 2029, at a CAGR of 8.1% from 2024 to 2029 according to a report published by MarketsandMarketstm. The growth of the beta-glucan market is...

at 05:00
Geekplus, the global leader in mobile robot and smart logistics solutions, has deployed the first Shelf-to-Person PopPick project in the Nordics for one of the biggest online pharmacy wholesalers in the region, Med24.dk. System Teknik partnered on...



News published on and distributed by: